Drug Profile
Research programme: inhaled dry powder respiratory therapeutics - MicroDose Therapeutx
Latest Information Update: 23 Sep 2014
Price :
$50
*
At a glance
- Originator Unknown
- Developer MicroDose Therapeutx
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 23 Sep 2014 Discontinued for Respiratory tract disorders (Inhalation)
- 08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries
- 01 Dec 2011 No development reported for Respiratory tract disorders (Inhalation)